C26 Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for C26 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 17.78 |
| 52 Week High | SEK 25.95 |
| 52 Week Low | SEK 16.08 |
| Beta | 1.22 |
| 1 Month Change | -5.02% |
| 3 Month Change | -30.14% |
| 1 Year Change | -2.31% |
| 3 Year Change | -40.93% |
| 5 Year Change | -46.04% |
| Change since IPO | -30.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| C26 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.6% | 0.9% | 1.3% |
| 1Y | -2.3% | -9.7% | 9.0% |
Return vs Industry: C26 exceeded the German Medical Equipment industry which returned -9.1% over the past year.
Return vs Market: C26 underperformed the German Market which returned 10.1% over the past year.
Price Volatility
| C26 volatility | |
|---|---|
| C26 Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C26 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: C26's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 228 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.
CellaVision AB (publ) Fundamentals Summary
| C26 fundamental statistics | |
|---|---|
| Market cap | €434.98m |
| Earnings (TTM) | €13.08m |
| Revenue (TTM) | €64.17m |
33.3x
P/E Ratio6.8x
P/S RatioIs C26 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C26 income statement (TTM) | |
|---|---|
| Revenue | SEK 737.16m |
| Cost of Revenue | SEK 243.34m |
| Gross Profit | SEK 493.83m |
| Other Expenses | SEK 343.61m |
| Earnings | SEK 150.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 6.30 |
| Gross Margin | 66.99% |
| Net Profit Margin | 20.38% |
| Debt/Equity Ratio | 4.6% |
How did C26 perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:12 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |